Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, a… Read more
Dermapharm Holding SE (DMPHF) - Net Assets
Latest net assets as of September 2025: $648.00 Million USD
Based on the latest financial reports, Dermapharm Holding SE (DMPHF) has net assets worth $648.00 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.12 Billion) and total liabilities ($1.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $648.00 Million |
| % of Total Assets | 30.55% |
| Annual Growth Rate | 27.68% |
| 5-Year Change | 87.41% |
| 10-Year Change | 1268.74% |
| Growth Volatility | 68.67 |
Dermapharm Holding SE - Net Assets Trend (2013–2024)
This chart illustrates how Dermapharm Holding SE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dermapharm Holding SE (2013–2024)
The table below shows the annual net assets of Dermapharm Holding SE from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $608.29 Million | +11.60% |
| 2023-12-31 | $545.05 Million | +2.36% |
| 2022-12-31 | $532.49 Million | +6.53% |
| 2021-12-31 | $499.83 Million | +53.99% |
| 2020-12-31 | $324.58 Million | +14.09% |
| 2019-12-31 | $284.49 Million | +11.09% |
| 2018-12-31 | $256.08 Million | +247.54% |
| 2017-12-31 | $73.69 Million | +21.18% |
| 2016-12-31 | $60.81 Million | +36.82% |
| 2015-12-31 | $44.44 Million | +30.67% |
| 2014-12-31 | $34.01 Million | -17.77% |
| 2013-12-31 | $41.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dermapharm Holding SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1177.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $433.19 Million | 71.67% |
| Common Stock | $53.84 Million | 8.91% |
| Other Comprehensive Income | $117.39 Million | 19.42% |
| Total Equity | $604.42 Million | 100.00% |
Dermapharm Holding SE Competitors by Market Cap
The table below lists competitors of Dermapharm Holding SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
secunet Security Networks Aktiengesellschaft
F:YSN
|
$310.29 Million |
|
Luenmei Quantum Co Ltd
SHG:600167
|
$310.32 Million |
|
Allgens Medical Technology Co. Ltd. A
SHG:688613
|
$310.34 Million |
|
Cembre S.p.A. Ord
LSE:0DXU
|
$310.46 Million |
|
MICROVAST HOLD. DL-0001
F:2OZA
|
$310.20 Million |
|
Mrs. Bectors Food Specialities Limited
NSE:BECTORFOOD
|
$310.10 Million |
|
9ZX0
F:9ZX0
|
$310.05 Million |
|
Shanghai Trendzone Decor Grp
SHG:603030
|
$310.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dermapharm Holding SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 539,207,000 to 604,422,000, a change of 65,215,000 (12.1%).
- Net income of 113,787,000 contributed positively to equity growth.
- Dividend payments of 47,379,000 reduced retained earnings.
- Other comprehensive income decreased equity by 753,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $113.79 Million | +18.83% |
| Dividends Paid | $47.38 Million | -7.84% |
| Other Comprehensive Income | $-753.00K | -0.12% |
| Other Changes | $-440.00K | -0.07% |
| Total Change | $- | 12.09% |
Book Value vs Market Value Analysis
This analysis compares Dermapharm Holding SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 75.33x to 3.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.53 | $39.56 | x |
| 2015-12-31 | $0.76 | $39.56 | x |
| 2016-12-31 | $1.06 | $39.56 | x |
| 2017-12-31 | $1.37 | $39.56 | x |
| 2018-12-31 | $4.73 | $39.56 | x |
| 2019-12-31 | $5.18 | $39.56 | x |
| 2020-12-31 | $5.98 | $39.56 | x |
| 2021-12-31 | $9.24 | $39.56 | x |
| 2022-12-31 | $9.87 | $39.56 | x |
| 2023-12-31 | $10.01 | $39.56 | x |
| 2024-12-31 | $11.20 | $39.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dermapharm Holding SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.83%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.64%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 3.44x
- Recent ROE (18.83%) is below the historical average (31.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -0.22% | -0.02% | 1.18x | 11.69x | $-2.89 Million |
| 2015 | 30.90% | 3.30% | 1.30x | 7.22x | $8.59 Million |
| 2016 | 29.56% | 3.79% | 1.43x | 5.48x | $11.13 Million |
| 2017 | 105.51% | 16.64% | 1.12x | 5.64x | $70.38 Million |
| 2018 | 29.84% | 13.16% | 0.81x | 2.79x | $50.08 Million |
| 2019 | 27.70% | 11.01% | 0.67x | 3.75x | $49.33 Million |
| 2020 | 26.66% | 10.81% | 0.65x | 3.80x | $53.63 Million |
| 2021 | 42.14% | 22.23% | 0.67x | 2.83x | $159.85 Million |
| 2022 | 25.25% | 13.10% | 0.73x | 2.66x | $81.08 Million |
| 2023 | 11.57% | 5.42% | 0.53x | 4.01x | $8.45 Million |
| 2024 | 18.83% | 9.64% | 0.57x | 3.44x | $53.34 Million |
Industry Comparison
This section compares Dermapharm Holding SE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dermapharm Holding SE (DMPHF) | $648.00 Million | -0.22% | 2.27x | $310.27 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |